ADAMTS13 conformation in remission in patients treated with or without caplacizumab
| . | Open conformation . | Closed conformation . |
|---|---|---|
| Caplacizumab (n = 82) | 32 (39%) | 49 (60%) |
| Noncaplacizumab (n = 37) | 19 (51) | 18 (49%) |
| . | Open conformation . | Closed conformation . |
|---|---|---|
| Caplacizumab (n = 82) | 32 (39%) | 49 (60%) |
| Noncaplacizumab (n = 37) | 19 (51) | 18 (49%) |
An open ADAMTS13 conformation was not more likely in patients treated with caplacizumab once remission is achieved (P = .2).